Leukemia Research

Papers
(The H4-Index of Leukemia Research is 17. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase65
Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia40
Acute leukemia in the time of COVID-1939
Venetoclax combination therapy in relapsed/refractory acute myeloid leukemia: A single institution experience39
Covid-19 infection in therapy-naive patients with B-cell chronic lymphocytic leukemia29
A concise review on the molecular genetics of acute myeloid leukemia29
Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study⋆28
Novel therapeutic approaches in chronic myeloid leukemia28
Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study26
Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia24
Advances in non-intensive chemotherapy treatment options for adults diagnosed with acute myeloid leukemia20
Exosome-derived miR-let-7c promotes angiogenesis in multiple myeloma by polarizing M2 macrophages in the bone marrow microenvironment19
Cannabinoid CP55940 selectively induces apoptosis in Jurkat cells and in ex vivo T-cell acute lymphoblastic leukemia through H2O2 signaling mechanism19
Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis19
Venetoclax and hypomethylating agent combination therapy in acute myeloid leukemia secondary to a myeloproliferative neoplasm18
A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival18
Plasma cell leukemia: A review of the molecular classification, diagnosis, and evidenced-based treatment17
0.064357042312622